Moreover, Acthar gel treatment markedly suppressed ex vivo myelin peptide-induced CD4+ T cell proliferation [33], as activation of T cells reactive to MBP was found in MS patients compared to healthy subjects [34]. This evidence concerns the gene MBP and myeloid sarcoma.